Francisco Torrens | Pharmacology | Breakthrough Research Award

Breakthrough Research Award

             Francisco Torrens
Affiliation Universitat de València
Country Spain
Scopus ID 56924529100
Documents 255
Citations 4,190
h-index 33
Subject Area Pharmacology
Event International Research Awards
ORCID 0000-0003-1737-2321

Francisco Torrens

Universitat de València, Spain

Francisco Torrens is a researcher affiliated with Universitat de València whose scholarly activities have contributed to pharmacology and related interdisciplinary scientific fields. His publication record, citation performance, and internationally indexed research profile demonstrate sustained academic engagement and measurable scientific influence. These achievements support recognition within competitive research award programs and international scholarly evaluations.[1]

Abstract

Francisco Torrens has established a distinguished academic profile through sustained research activity, international publications, and measurable scientific influence within pharmacology and interdisciplinary computational sciences. His Scopus-indexed record includes 255 publications, more than 4,190 citations, and an h-index of 33, reflecting consistent scholarly productivity and broad research visibility. His work has supported scientific understanding through theoretical investigations, collaborative studies, and methodological developments that contribute to international research communities. These achievements demonstrate academic excellence, research continuity, and global scholarly recognition, making his profile well aligned with the objectives and evaluation standards of the Breakthrough Research Award.[1][2]

Keywords

Pharmacology, Computational Chemistry, Molecular Modeling, Drug Discovery, Scientific Research, Scopus Author, Citation Impact, International Research Awards, Breakthrough Research Award, Research Excellence.

Introduction

Scientific recognition is founded upon sustained research productivity, scholarly quality, and measurable academic influence. Francisco Torrens has developed an established research career supported by extensive publications, international collaborations, and consistent citation performance that reflects the relevance of his scientific contributions within pharmacology and computational research disciplines.[1]

Research Profile

Based at Universitat de València, Francisco Torrens has maintained an internationally visible academic profile indexed by Scopus and ORCID. His publication metrics demonstrate long-term scholarly engagement while supporting interdisciplinary research activities across pharmacology, computational chemistry, molecular science, and related analytical methodologies.[1]

Research Contributions

His research contributions emphasize theoretical investigations, computational approaches, molecular characterization, and scientific modeling that enhance understanding of biologically relevant systems. Through peer-reviewed publications and collaborative research, he has contributed valuable knowledge supporting evidence-based scientific advancement across multiple research domains.[2]

Publications

Francisco Torrens has authored or co-authored 255 Scopus-indexed publications that collectively demonstrate consistent scholarly productivity. His publications have appeared in internationally recognized scientific journals, contributing to ongoing developments in pharmacology, computational chemistry, molecular science, and interdisciplinary biomedical research.[1]

Research Impact

With more than 4,190 citations and an h-index of 33, his research demonstrates sustained academic influence across international scientific literature. These bibliometric indicators illustrate the continued relevance, visibility, and utilization of his published work within the global research community.[3]

Award Suitability

The Breakthrough Research Award recognizes researchers demonstrating significant scholarly achievement, measurable scientific impact, and continued research excellence. Francisco Torrens satisfies these evaluation criteria through his publication record, citation performance, interdisciplinary collaborations, and internationally recognized academic profile.[4]

Conclusion

Francisco Torrens represents an accomplished researcher whose scholarly record reflects sustained productivity, scientific influence, and international visibility. His research achievements, recognized publication metrics, and established academic profile support his suitability for consideration within the International Research Awards and similar programs recognizing research excellence.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Francisco Torrens. Author ID 56924529100. Scopus.
    https://www.scopus.com/pages/authors/56924529100
  2. ORCID. (n.d.). ORCID author details: Francisco Torrens.
    https://orcid.org/0000-0003-1737-2321
  3. International Research Awards. (n.d.). Breakthrough Research Award.
    https://researchawards.net/
  4. Sandoval-Vásquez, C., Cárcamo, I., Lagos, P., Muñoz, A., Zavala, F., Colil, V., Villagrán-Silva, F., Vásquez-Carrasco, E., Hernandez-Martinez, J., Valdés-Badilla, P., Torrens, F., Fincheira, P., & Sepúlveda, P. (2025). Effectiveness of drug-loaded poly(ethylene glycol) and poly(lactic-co-glycolic-acid) nanoparticles in the in vitro treatment of breast cancer: A systematic review. Frontiers in Pharmacology, 16, 1710176.
    https://doi.org/10.3389/fphar.2025.1710176
  5. Canizares-Carmenate, Y., Perez-Gimenez, F., Diaz-Amador, R., Torrens, F., & Castillo-Garit, J. A. (2025). Discovery of diphenylsilane compounds as potential inhibitors of Zn-metalloproteinase thermolysin using artificial neural networks. Current Computer-Aided Drug Design. Advance online publication.
    https://doi.org/10.2174/0115680266369656250428053942

Francesco Ferrara | Pharmacist | Innovative Research Award

Innovative Research Award

Francesco Ferrara – ASL Napoli 3 SUD, Italy
Francesco Ferrara
Affiliation ASL Napoli 3 SUD
Country Italy
Scopus ID 59464334600
Documents 1546
Citations 2176
h-index 27
Subject Area Pharmacist
Event International Research Awards
ORCID 0000-0001-9298-6783

Francesco Ferrara is an Italian hospital pharmacist and researcher affiliated with ASL Napoli 3 SUD. His academic profile demonstrates extensive contributions to pharmacology, clinical pharmacy, healthcare governance, and therapeutic innovation. Through a substantial publication record and active international collaboration, he has contributed to evidence-based healthcare practices and multidisciplinary medical research.[1]

Abstract

This article evaluates the scholarly profile of Francesco Ferrara in relation to the Innovative Research Award. His research activities encompass pharmacology, healthcare management, antimicrobial resistance, chronic disease treatment, and pharmaceutical policy. The combination of publication productivity, citation influence, and interdisciplinary engagement highlights a sustained commitment to advancing healthcare knowledge and clinical practice.[1]

Keywords

Pharmacology, Clinical Pharmacy, Healthcare Governance, Drug Policy, Therapeutic Innovation, Antimicrobial Resistance, Pharmaceutical Research.

Introduction

Modern healthcare requires researchers capable of integrating clinical evidence, pharmaceutical management, and public health priorities. Francesco Ferrara has developed a multidisciplinary portfolio addressing therapeutic effectiveness, healthcare sustainability, and emerging treatment strategies. His work reflects contemporary priorities in patient-centered care and pharmaceutical innovation.[2]

Research Profile

Ferrara serves within the Italian Health Service and has accumulated professional experience across multiple healthcare institutions. His expertise includes clinical pharmacy, pharmacoeconomics, healthcare technology assessment, and pharmaceutical governance. The researcher maintains active participation in scientific publishing and peer-review activities across internationally recognized journals.[1]

Research Contributions

Key contributions include investigations into antimicrobial resistance, biosimilar medicines, chronic disease management, neurological disorders, dermatological therapies, and healthcare expenditure analysis. His research frequently combines clinical relevance with policy implications, supporting informed decision-making in healthcare systems and pharmaceutical practice.[3]

Publications

Publications

Francesco Ferrara has authored and co-authored an extensive portfolio of scholarly publications spanning pharmacology, clinical pharmacy, antimicrobial resistance, chronic disease management, dermatology, neurology, cardiovascular medicine, and healthcare governance. His research has appeared in internationally recognized journals including Inflammopharmacology, European Journal of Clinical Pharmacology, Pharmaceuticals, Antibodies, and Hospital Pharmacy. Through collaborations with multidisciplinary research teams, he has contributed to studies addressing therapeutic innovation, drug utilization, public health challenges, and evidence-based healthcare policies. The breadth and consistency of his publication record demonstrate sustained scientific productivity and a commitment to advancing pharmaceutical and clinical research across diverse healthcare settings.[2][3]

Research Impact

With more than two thousand citations and a substantial h-index, Ferrara’s scholarly output demonstrates measurable academic influence. His studies contribute to clinical practice, healthcare policy development, and pharmaceutical governance. The broad thematic coverage of his work illustrates a capacity to address both specialized and system-level healthcare challenges.[1]

Award Suitability

The Innovative Research Award recognizes individuals who demonstrate originality, sustained scholarly productivity, and meaningful research outcomes. Ferrara’s record of publications, international collaborations, and healthcare-focused investigations aligns with these criteria. His contributions support innovation in pharmacological science and evidence-based healthcare management.[4]

Conclusion

Francesco Ferrara has established a notable academic profile through sustained research activity, clinical expertise, and interdisciplinary collaboration. His contributions to pharmacology and healthcare policy provide practical and scholarly value. These achievements support his recognition as a strong candidate for the Innovative Research Award.[5]

References

    1. ORCID. (2026). Francesco Ferrara (ORCID iD: 0000-0001-9298-6783). ORCID Registry.
      https://orcid.org/0000-0001-9298-6783
    2. Ferrara, F., De Berardinis, F., Scognamiglio, M., & Zovi, A. (2026). The shifting paradigm of monoclonal antibodies in COVID-19 management: From early triumphs to viral resistance and future perspectives. Antibodies, 15(3), Article 48.
      https://doi.org/10.3390/antib15030048
    3. Ferrara, F. (2026). Therapeutic update on alopecia areata: A critical review of standard and emerging targeted therapies. Inflammopharmacology.
      https://doi.org/10.1007/s10787-026-02273-8
    4. Ferrara, F., Martellone, L., Vaccaro, M., Coluccia, A., Scognamiglio, M., Langella, R., Zovi, A., & Polito, G. (2025). Real-life impact of cefiderocol in carbapenem-resistant Acinetobacter baumannii infections (CRAb): A narrative review. European Journal of Clinical Pharmacology.
      https://doi.org/10.1007/s00228-025-03866-y
    5. Elsevier. (2026). Scopus Author Profile: Francesco Ferrara (Author ID: 59464334600). Scopus Preview.
      https://www.scopus.com/authid/detail.uri?authorId=59464334600

Dengning Xia | Pharmacology | Best Researcher Award

Prof. Dengning Xia | Pharmacology | Best Researcher Award 

Prof. Dengning Xia, Sun Yat-sen University, China

Dr. Dengning Xia is an Associate Professor and Principal Investigator at the School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, China. With a Ph.D. in Pharmaceutics and international training experience in Denmark and the U.S., his research focuses on industrial pharmaceutics, biopharmaceutics, and biomedical engineering for drug and vaccine delivery. His work explores microneedle systems, nucleic acid and oral delivery, and translational drug formulation. He has received numerous talent awards, serves on editorial boards of leading journals, and has published over 40 peer-reviewed papers in top-tier pharmaceutical and biomedical journals.

Author Profile

Google  Scholar

🎓 Early Academic Pursuits

Dr. Dengning Xia’s academic journey reflects a strong and consistent commitment to the pharmaceutical sciences. He began his higher education with a Bachelor’s degree in Pharmacy from the School of Pharmacy, Hunan University of Chinese Medicine in 2005. Demonstrating early promise and dedication, he continued his studies with a Master’s degree in Pharmaceutics from West China School of Pharmacy, Sichuan University (2005–2008), a program known for its rigorous training and focus on drug delivery systems. Pushing the boundaries of academic excellence, Dr. Xia earned his Ph.D. in Pharmaceutics from Shenyang Pharmaceutical University (2008–2011). As part of his doctoral training, he participated in a joint research program at the University of Copenhagen in Denmark (2011), gaining valuable international research exposure and advancing his expertise in advanced drug delivery systems. His early academic experiences laid the foundation for a research career focused on innovation in pharmaceutical technologies.

🧪 Professional Endeavors

Dr. Xia’s professional journey spans globally recognized institutions and industry positions, reflecting his deep-rooted experience across both academic and applied pharmaceutical sciences. Following a brief stint as Formulation Project Leader at Shanghai Haini Pharmaceutical Co., Ltd. (2011–2012), he moved into academia and research as a Postdoctoral Fellow and later Associate Researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2012–2017). His passion for translational research took him to the United States, where he worked at the University of Connecticut and later as a Postdoctoral Fellow and Research Scientist at the School of Chemical and Biomolecular Engineering, Georgia Institute of Technology (2017–2020). Since 2020, Dr. Xia has been serving as an Associate Professor (PI) at the School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, a role he assumed under the prestigious “Hundred Talents Program.”

🔬 Contributions and Research Focus

Dr. Xia’s research spans industrial pharmaceutics, biopharmaceutics, and biomedical engineering, with a consistent focus on overcoming biological barriers in drug and vaccine delivery. His multidisciplinary work has led to impactful contributions in the following areas:

  1. 🧬 Overcoming Biological Barriers in Drug Delivery: He has developed innovative microneedle technologies, gastrointestinal and ocular drug delivery systems, and long-acting formulations that enhance therapeutic efficacy while minimizing toxicity.

  2. 💉 Vaccine and Nucleic Acid Delivery Systems: Leveraging cutting-edge piezoelectric systems and novel carriers, Dr. Xia is pioneering advancements in gene and vaccine delivery platforms, including low-cost electroporators and skin-based delivery.

  3. 🏥 Clinical Translation: His translational research bridges laboratory discoveries with clinical applications, facilitating the development of scalable pharmaceutical formulations and devices.

With over 40 high-impact publications, including in PNAS, Advanced Functional Materials, Journal of Controlled Release, and Science Robotics, Dr. Xia’s work is globally cited and well-respected.

🏆 Accolades and Recognition

Dr. Xia’s innovative work has earned him numerous awards and prestigious appointments:

  • “Pearl River Talents Program” Young Top-notch Talent – Guangdong Province

  • Pengcheng Peacock Plan – High-level Talent, Shenzhen

  • Outstanding Young Talent – Sanofi-CAS Shanghai Institute of Biological Sciences

  • Youth Innovation Promotion Association Member – Chinese Academy of Sciences

He serves on editorial boards for top journals such as the European Journal of Pharmaceutics and Biopharmaceutics and Asian Journal of Pharmaceutical Sciences, and is a trusted peer reviewer for over 10 major journals and national grant programs.

🌍 Impact and Influence

Dr. Xia’s work has significantly advanced the field of drug delivery science, particularly through his innovations in microneedle patches, oral and ocular formulations, and nucleic acid therapeutics. His research not only addresses practical clinical challenges but also offers low-cost, accessible solutions for global healthcare, such as vaccine patches for diseases like SARS-CoV-2 and Ebola. His collaborative projects with international scientists from the U.S., China, and Europe have amplified his impact, making him a key influencer in pharmaceutical formulation research and a valuable mentor to the next generation of scientists.

🧭 Legacy and Future Contributions

Looking ahead, Dr. Xia’s legacy will likely be defined by his ability to combine academic rigor with real-world solutions. His contributions to microneedle-based technologies and oral delivery systems are poised to transform how vaccines and drugs are administered, especially in low-resource settings. As a principal investigator and educator at Sun Yat-sen University, he continues to mentor emerging scientists, foster international collaborations, and push the boundaries of what’s possible in drug delivery science. With his track record, Dr. Xia is set to play a leading role in the next generation of pharmaceutical innovation, particularly in the realms of biodegradable drug carriers, smart delivery systems, and personalized medicine.

✍️Publication Top Notes


📘Preparation of stable nitrendipine nanosuspensions using the precipitation–ultrasonication method for enhancement of dissolution and oral bioavailability

Author: D Xia, P Quan, H Piao, H Piao, S Sun, Y Yin, F Cui

Journal: European journal of pharmaceutical sciences 

Year: 2010


📘Devices, Systems, and Methods for Facilitating Tissue Delivery of Drug

Author: MS Bhamla, G Byagathvalli, D Xia, MR Prausnitz

Journal: US Patent App

Year: 2023


📘Inflammation-retentive hyaluronic acid-mesalamine conjugate for enhanced oral therapy in ulcerative colitis

Author: Y Hou, J Yao, J Hu, D Xia

Journal: International Journal of Biological Macromolecules

Year: 2025